Entrada Therapeutics, Inc. TRDA
Biotechnology: Pharmaceutical Preparations · IPO 2021 · data as of November 13, 2026
Entrada Therapeutics, Inc. (TRDA) is a healthcare company listed in the US with a market value of about $199M. In the twelve months to September 30, 2026 it had revenue of $4M and net income of -$161M, a net margin of -4058.0%.
Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -15%.
About Entrada Therapeutics
Entrada Therapeutics is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2021. It was profitable in 1 of the last 6 years in our data. Its share count rose by 32% over three years (dilution for shareholders). It spends 560% of revenue on research and development.
Score: 0.6 / 5
Checks passed
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 6 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Revenue | $4M | $25M | $211M | $129M | — | — | — |
| Net income | -$161M | -$144M | $66M | -$7M | -$95M | -$51M | -$27M |
| Free cash flow | -$136M | -$130M | -$45M | $134M | -$97M | -$55M | -$28M |
| EPS (diluted) | $-3.84 | $-3.47 | $1.68 | $-0.20 | $-3.02 | $-8.16 | $-24.00 |
| Net margin | -4058.0% | -565.5% | 31.1% | -5.2% | — | — | — |
| ROIC | — | -34.9% | 7.6% | -0.8% | -32.2% | -13.5% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Does Entrada Therapeutics pay a dividend?
Not currently.
Is Entrada Therapeutics a good stock to buy?
We do not give buy or sell advice. Entrada Therapeutics scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.